CeriBell Inc. is a commercial-stage medical technology company. It focused on transforming the diagnosis and management of patients with serious neurological conditions. The company is an AI-powered, rapidly deployable point-of-care electroencephalography platform designed to address the unmet needs of patients in the acute care setting. CeriBell Inc. is based in Sunnyvale, Calif.
| Revenue (Most Recent Fiscal Year) | $65.44M |
| Net Income (Most Recent Fiscal Year) | $-40.46M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.39 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -61.82% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 17.36 |
| Quick Ratio (Most Recent Fiscal Quarter) | 16.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.11 |
| Inventory Turnover (Trailing 12 Months) | 1.26 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.00 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.39 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 36.14M |
| Free Float | 28.88M |
| Market Capitalization | $615.15M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.10% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |